How India Exports Daunorubicin to the World

Daunorubicin, an anthracycline antibiotic used primarily in the treatment of acute myeloid leukemia (AML), has been a critical component in chemotherapy regimens. According to the FDA's Orange Book, multiple Abbreviated New Drug Applications (ANDAs) for daunorubicin have been approved, indicating a well-established generic market presence. The most recent approval was granted in June 2025, reflecting ongoing interest and investment in this therapeutic area.

Despite the presence of numerous approved ANDAs, the U.S. market for daunorubicin remains competitive. The absence of current import alerts related to daunorubicin suggests that Indian exporters are maintaining compliance with FDA standards. However, with 113 active Indian exporters and 167 buyers, the market is fragmented, necessitating stringent adherence to regulatory requirements to ensure market access and competitiveness.

In the European Union, daunorubicin has been recognized for its therapeutic value in treating AML. Notably, in December 2008, the European Medicines Agency (EMA) granted orphan designation to liposomal daunorubicin for the treatment of AML, highlighting its significance in addressing this rare condition. This designation underscores the EU's commitment to facilitating the development of treatments for rare diseases.

Manufacturers exporting daunorubicin to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These standards ensure the quality and safety of pharmaceutical products, and adherence is mandatory for market authorization.

Daunorubicin is listed in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion signifies its critical role in treating priority health conditions globally. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, promoting access to vital treatments.

Regarding pharmacopoeial standards, daunorubicin is included in major compendia such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is essential for ensuring the quality and efficacy of the drug across different markets.

In India, daunorubicin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. This classification mandates that daunorubicin can only be sold with a valid prescription from a registered medical practitioner.

The National Pharmaceutical Pricing Authority (NPPA) oversees the pricing of essential medicines in India. As of March 2026, daunorubicin is subject to price control under the Drug Price Control Order (DPCO), ensuring its affordability and accessibility. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of daunorubicin, ensuring compliance with national regulations.

The primary patents for daunorubicin have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has contributed to the drug's affordability and widespread availability.

In June 2025, the FDA approved a new generic formulation of daunorubicin, enhancing treatment options for AML patients. This approval reflects the ongoing efforts to increase access to essential chemotherapy agents.

In September 2025, the WHO updated its Model List of Essential Medicines, reaffirming daunorubicin's inclusion and emphasizing its importance in global health. This update serves as a guideline for countries to prioritize essential medicines in their healthcare systems.

In December 2025, the EMA issued new guidelines on the manufacturing of anthracycline antibiotics, including daunorubicin, to enhance quality control measures. These guidelines aim to ensure the safety and efficacy of these critical medications.

In January 2026, the NPPA revised the ceiling price for daunorubicin under the DPCO, reflecting changes in production costs and market dynamics. This revision aims to balance affordability for patients with sustainability for manufacturers.

In February 2026, the CDSCO implemented stricter export NOC requirements for daunorubicin to ensure compliance with international quality standards. These measures are intended to maintain the reputation of Indian pharmaceutical exports in global markets.

Daunorubicin, an anthracycline antibiotic used in chemotherapy, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, indicating a significant concentration risk in the pharmaceutical supply chain.

Recent disruptions have highlighted the vulnerabilities associated with this reliance. In September 2020, China increased prices of key drug materials by 10-20%, impacting the cost structures of Indian pharmaceutical manufacturers. Such price hikes can discourage indigenous API production, making it less competitive against Chinese products globally.

Our proprietary trade data indicates that the top five Indian exporters of Daunorubicin account for 44.1% of the total export value, with BIOZENTA LIFESCIENCE PRIVATE LIMITED leading at 12.6%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a step towards self-reliance.

Geopolitical tensions and shipping disruptions pose additional risks to the Daunorubicin supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for pharmaceutical exports; any instability in these regions can delay shipments and increase costs. Furthermore, escalating U.S.-China tensions have led to increased scrutiny and potential tariffs on pharmaceutical imports, affecting the availability and pricing of essential drugs.

Regulatory bodies have also reported shortages linked to manufacturing disruptions. For instance, in October 2025, Health Canada reported a shortage of Daunorubicin Hydrochloride Injection due to manufacturing issues, with an estimated resolution by March 2026. (drugshortagescanada.ca)

• Diversify Sourcing: Identify and qualify alternative suppliers for KSMs and APIs to reduce dependency on a single country or supplier.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical KSMs and APIs to strengthen supply chain resilience.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain.

• Strengthen Supplier Relationships: Develop strategic partnerships with key suppliers to ensure priority access during disruptions.

• Implement Risk Assessment Protocols: Regularly conduct comprehensive risk assessments to identify vulnerabilities and develop contingency plans.

RISK_LEVEL: MEDIUM